Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 28Colorectal Neoplasms 8Lung Neoplasms 7Neoplasms 6Melanoma 5Thyroid Neoplasms 3Pancreatic Neoplasms 3Glioma 3Adenocarcinoma of Lung 3Rectal Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sexual Dysfunction, Physiological 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Prostatic Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1

Interventions

Carboplatin 12Pemetrexed 11pembrolizumab 10Paclitaxel 6Cisplatin 6Erlotinib Hydrochloride 5Docetaxel 5Nivolumab 4Gefitinib 4spartalizumab 3osimertinib 3Gemcitabine 3EC145 3Crizotinib 3Afatinib 3technetium 99m etarfolatide 2pralsetinib 2fludarabine 2cemiplimab 2brigatinib 2alpha-2'-deoxythioguanosine 2aldesleukin 2Vinorelbine 2Radiotherapy 2Quality of Life 2MORAb-202 2Immunotherapy 2Drug Therapy 2Cyclophosphamide 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × trametinib × Thoracic × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔